Cubist Pharmaceuticals Inc. (CBST)
-NasdaqGS 56.11 
0.65(1.17%) 04:00 SGT|After Hours
:
56.11 0.00 (0.00%) 04:31 SGT
| Prev Close: | 55.46 |
|---|
| Open: | 55.22 |
|---|
| Bid: | 48.00 x 300 |
|---|
| Ask: | 60.00 x 100 |
|---|
| 1y Target Est: | 52.00 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | 54.92 - 56.54 |
|---|
| 52wk Range: | 36.73 - 56.54 |
|---|
| Volume: | 1,270,054 |
|---|
| Avg Vol (3m): | 877,597 |
|---|
| Market Cap: | 3.66B |
|---|
| P/E (ttm): | 31.24 |
|---|
| EPS (ttm): | 1.80 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cubist Pharmaceuticals Inc. (CBST): Today's Featured Health Care Winnerat TheStreet(Thu, 05:00 SGT)
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tapat TheStreet(Wed, 22 May)
- Cubist Rises On Unusually High Volume (CBST)at TheStreet(Wed, 22 May)
- Ahead of the Bell: Analyst upgrades Cubist PharmaAP(Tue, 21 May)
- Ahead of the Bell: Analyst upgrades Cubist PharmaAP(Tue, 21 May)
- Analysts' Actions: CBST CNW COH TMHC VFCTheStreet(Tue, 21 May)
- Cubist price target raised to $63 from $53 at RBC Capitaltheflyonthewall.com(Tue, 21 May)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, 21 May)
- Cubist antibiotic regimen gets fast-track reviewAP(Wed, 8 May)
- Alnylam takes smaller 1Q loss on lower costsAP(Tue, 7 May)
Key Statistics
| Forward P/E (1 yr): | 31.52 |
|---|
| P/S (ttm): | 3.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.37 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.37 |
|---|
Business Summary
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States.
View More